Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes
Open Access
- 6 October 2009
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 32 (12), 2251-2257
- https://doi.org/10.2337/dc09-0773
Abstract
OBJECTIVE: In patients with long-standing type 1 diabetes, we investigated whether improved β-cell function can be achieved by combining intensive insulin therapy with agents that may 1) promote β-cell growth and/or limit β-cell apoptosis and 2) weaken the anti–β-cell autoimmunity. RESEARCH DESIGN AND METHODS: For this study, 20 individuals (mean age 39.5 ± 11.1 years) with long-standing type 1 diabetes (21.3 ± 10.7 years) were enrolled in this prospective open-label crossover trial. After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab. Endogenous insulin production was determined by repeatedly measuring serum C-peptide. RESULTS: In 85% of individuals with long-standing type 1 diabetes who were screened for participation in this trial, C-peptide levels ≥0.05 ng/ml (0.02 nmol/l) were found. Residual β-cells responded to physiological (mixed-meal) and pharmacological (arginine) stimuli. During exenatide treatment, patients lost 4.1 ± 2.9 kg body wt and insulin requirements declined significantly (total daily dose on exenatide 0.48 ± 0.11 vs. 0.55 ± 0.13 units · kg−1 · day−1 without exenatide; P = 0.0062). No signs of further activation of the underlying autoimmune disease were observed. Exenatide delayed gastric emptying, suppressed endogenous incretin levels, but did not increase C-peptide secretion. CONCLUSIONS: In long-standing type 1 diabetes, which remains an active autoimmune disease even decades after its onset, surviving β-cells secrete insulin in a physiologically regulated manner. However, the combination of intensified insulin therapy, exenatide, and daclizumab did not induce improved function of these remaining β-cells.This publication has 26 references indexed in Scilit:
- Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograftDiabetologia, 2009
- Exendin‐4 Therapy in NOD Mice with New‐Onset Diabetes Increases Regulatory T Cell FrequencyAnnals of the New York Academy of Sciences, 2008
- GAD Treatment and Insulin Secretion in Recent-Onset Type 1 DiabetesThe New England Journal of Medicine, 2008
- Exendin-4 Does Not Promote Beta-Cell Proliferation or Survival During the Early Post-Islet Transplant Period in MiceTransplantation Proceedings, 2008
- Glucose Infusion in MiceDiabetes, 2007
- Growth and Regeneration of Adult β Cells Does Not Involve Specialized ProgenitorsDevelopmental Cell, 2007
- Cross-over trials inStatistics in Medicine: the first ‘25’ yearsStatistics in Medicine, 2006
- Analysis of T-Cell Assays to Measure Autoimmune Responses in Subjects With Type 1 DiabetesDiabetes, 2006
- Initial Evaluation of Subcutaneous Daclizumab Treatments for Noninfectious Uveitis: A Multicenter Noncomparative Interventional Case SeriesOphthalmology, 2005
- Benefits and Risks of Solitary Islet Transplantation for Type 1 Diabetes Using Steroid-Sparing ImmunosuppressionDiabetes Care, 2003